AKBA vs AMGN · rev $102.7M vs P/E 24, rev $10.05B
Akebia Ther (AKBA) versus Amgen Inc (AMGN) — a side-by-side from cached financials, not a winner call.
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Latest reported AKBA revenue for 2026-06-30 was $102.7M. Net income was -$18.0M. Revenue was up 91.8% from 2026-03-31 to 2026-06-30. AKBA currently screens at market cap $260.1M.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
AKBA currently screens at market cap $260.1M. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Not investment advice. Open the AKBA and AMGN stock pages for the full models.
Not investment advice.